» Articles » PMID: 32368069

Longitudinal Progression of Estimated GFR in HIV-1-Infected Patients with Normal Renal Function on Tenofovir-Based Therapy in China

Overview
Publisher Dove Medical Press
Date 2020 May 6
PMID 32368069
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Estimated glomerular filtration rate (eGFR) decline in HIV-1-infected patients exposure to tenofovir disoproxil fumarate (TDF) has been widely assessed using linear models, but nonlinear assumption is not well validated. We constructed a retrospective cohort study to assess whether eGFR decline follows nonlinearity during antiviral therapy.

Patients And Methods: We examined 823 (299 of TDF users and 524 of non-TDF users) treatment-naïve HIV-1-infected participants (age ≥ 17 years, initial eGFR ≥ 90 mL/min/1.73m). Estimated GFR trajectories were compared by one-linear and piecewise-linear mixed effects models, before and after propensity score matching, respectively. Whether the incidence of renal dysfunction (reduced renal function [RRF], eGFR < 90 mL/min/1.73 m and rapid kidney function decline [RKFD], eGFR > -3 mL/min/1.73 m/year) follows nonlinearity was assessed by logistic regression.

Results: The median follow-up time of this study was 10 (interquartile range, 2-20) months, during which 178 (21.6%) experienced RRF, and 451 (54.8%) experienced RKFD. The slopes (mL/min/1.73 m/year) of eGFR were -5.31 (95% CI: -6.57, -4.06) before 1.40 years, 4.83 (95% CI: 1.38, 8.28) from years 1.40 to 2.30 and -3.71 (95% CI: -5.97, -1.45) after 2.30 years among TDF users. Within years 1.40-2.30, each year of TDF exposure was associated with a 78% decreased risk of RKFD (95% CI: -91%, -49%). In comparison, eGFR increased slightly at the initiation of antiviral therapy, declined after 2.15 years (-4.96; 95% CI: -5.76, -4.17) among non-TDF users. Such a progression nonlinear trajectory was missed on the assumption of one-linearity, whether in TDF or non-TDF users.

Conclusion: Over the piecewise mixed-effects analyses with the advantage of revealing the true nature of the exposure outcome relationships, an interesting reverse S-shaped relationship was observed. A routine screen based on nonlinearity could be more helpful for patient management.

Citing Articles

Impact of estimated glomerular filtration rate (eGFR) on in-hospital mortality: an age- and HIV status-specific retrospective cohort study in Uganda.

Christopher O, Yanmei W, Yeko M, Nanyunja D, Kabbali K BMC Nephrol. 2025; 26(1):43.

PMID: 39875843 PMC: 11776265. DOI: 10.1186/s12882-025-03976-w.


Factors Associated with Antiretroviral Therapy Toxicity Out-Comes in Patients with and without Hypertension.

Dlamini S, Wu M, Dahms H Int J Environ Res Public Health. 2022; 19(17).

PMID: 36078765 PMC: 9518525. DOI: 10.3390/ijerph191711051.


Incidence of impaired kidney function among people with HIV: a systematic review and meta-analysis.

Shi R, Chen X, Lin H, Ding Y, He N BMC Nephrol. 2022; 23(1):107.

PMID: 35300612 PMC: 8932163. DOI: 10.1186/s12882-022-02721-x.

References
1.
Jose S, Hamzah L, Campbell L, Hill T, Fisher M, Leen C . Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. J Infect Dis. 2014; 210(3):363-73. PMC: 4091582. DOI: 10.1093/infdis/jiu107. View

2.
Stevens L, Coresh J, Greene T, Levey A . Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006; 354(23):2473-83. DOI: 10.1056/NEJMra054415. View

3.
Austin P . Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes. 2009; 1(1):62-7. DOI: 10.1161/CIRCOUTCOMES.108.790634. View

4.
Estrella M, Moosa M, Nachega J . Editorial commentary: Risks and benefits of tenofovir in the context of kidney dysfunction in sub-Saharan Africa. Clin Infect Dis. 2014; 58(10):1481-3. PMC: 4001289. DOI: 10.1093/cid/ciu123. View

5.
Zachor H, Machekano R, Estrella M, Veldkamp P, Zeier M, Uthman O . Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens. AIDS. 2016; 30(8):1221-8. PMC: 5027227. DOI: 10.1097/QAD.0000000000001041. View